Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
D609714-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $49.90 | |
D609714-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $119.90 | |
D609714-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $219.90 | |
D609714-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $369.90 | |
D609714-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $549.90 | |
D609714-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $789.90 |
Synonyms | 219311-44-1 (free base) | A911600 | N-(6-Chloro-3-((4,5-dihydro-1H-imidazol-2-yl)methoxy)-2-methylphenyl)methanesulfonamide | Dabuzalgron | HY-117071 | Dabuzalgron [INN] | CHEBI:142452 | GTPL3469 | LGX4GZ74WO | EX-A4502 | METHANESULFONAMIDE, N-(6-CHLORO-3 |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST, PARTIAL AGONIST |
Mechanism of action | Alpha-1a adrenergic receptor partial agonist |
Product Description |
Dabuzalgron (Ro 115-1240) is a selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.
|
ALogP | 0.9 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methylphenyl]methanesulfonamide |
---|---|
INCHI | InChI=1S/C12H16ClN3O3S/c1-8-10(19-7-11-14-5-6-15-11)4-3-9(13)12(8)16-20(2,17)18/h3-4,16H,5-7H2,1-2H3,(H,14,15) |
InChi Key | FOYWMEJSRSBQGB-UHFFFAOYSA-N |
Canonical SMILES | Clc1ccc(c(c1NS(=O)(=O)C)C)OCC1=NCCN1 |
Isomeric SMILES | CC1=C(C=CC(=C1NS(=O)(=O)C)Cl)OCC2=NCCN2 |
PubChem CID | 216249 |
Molecular Weight | 317.79 |
CAS Registry No. | 219311-44-1 |
---|---|
PubChem CID | 216249 |
ChEMBL Ligand | CHEMBL257978 |
GPCRdb Ligand | dabuzalgron |
Enter Lot Number to search for COA: